Bremelanotide, explained.
PT-141 (Vyleesi). Research, safety questions, and treatment context.
The form
More than one catalog form
The routine
The approved injection is used as needed.
The evidence
Large human trials for a specific injectable use
Forms listed in a June 2025 catalog. Current availability and individual instructions need confirmation.
On this page
A linked source is not a clinical endorsement. How we handle review and corrections.
- Legal status
- FDA-approved drug
FDA-approved in 2019 as Vyleesi for premenopausal women with low sexual desire. Use in men is off-label.
- At Goodmorrow
- Offered when we open
What it is
Bremelanotide activates melanocortin receptors in the brain that are involved in sexual desire. Vyleesi is a small injection you give yourself about 45 minutes before sex, as needed.
What the evidence shows
In the trials behind its approval, women taking it reported a modest increase in desire and less distress about low desire compared with placebo. Evidence in men comes from earlier, smaller studies.
How Goodmorrow handles it
We check your blood pressure and history first, then prescribe the FDA-approved product.
Before you take it
- Nausea is common, especially the first time. It briefly raises blood pressure, so it isn't for people with uncontrolled high blood pressure or heart disease.
- The label limits it to one dose in 24 hours and eight doses a month. Some people notice darkening of the skin in small patches with repeated use.
Questions people ask
Does PT-141 work for men?
Vyleesi is approved for women. Men use it off-label, and the evidence comes from earlier, smaller studies. It acts on desire, not erections, so it's a different tool from Viagra or Cialis.
Sources
- FDA documentVyleesi (bremelanotide injection) prescribing information U.S. Food and Drug Administration, 2019
Good days ahead.
Join the opening list for appointment updates.